What ring vaccination proved — and what the supply chain has to deliver
The case for treating campaign logistics as the binding constraint rests on one of the most striking results in modern field epidemiology. In the 2015 Guinea ring-vaccination trial ("Ebola Ça Suffit!"), the rVSV-ZEBOV vaccine showed a vaccine efficacy of 100 percent against laboratory-confirmed Ebola disease across a trial population of roughly 11,800 people — vaccinating the contacts of confirmed cases, and the contacts of those contacts, rather than blanketing a population. A vaccine that good redraws the whole logistics problem: the constraint is no longer dose volume but reaching a small, specific, fast-moving list of people, quickly, with a dose that has stayed potent across the last mile.
That last clause is where campaigns are won or lost. Most campaign antigens must hold a +2 to +8°C window from depot to arm, and several adjuvanted antigens are inactivated, invisibly and irreversibly, by even a brief excursion below 0°C — which is why ice packs are conditioned to the point of sweating before they go into a carrier. Supply itself is fragile: in 2024 the global oral-cholera-vaccine stockpile ran empty, requests for 8.4 million doses over six weeks could only be partly filled, and a deficit of tens of millions of doses persisted through the year, forcing reactive campaigns to be prioritised over preventive ones. When every dose is that scarce, a freeze excursion or an unsupervised handover is not a logistics footnote — it is a discarded immunisation the world could not spare.